These real-world observations on BCP’s observed benefits in hyperglycemia, inflammation, and organ protection underscore the clinical relevance of original in vitro studies that identified its CB2 agonist and PPAR activator properties, suggesting a broader, multi-targeted therapeutic action beyond direct SGLT2 inhibition that complements traditional diabetes management strategies. Here, SLC5A2 is linked to diabetes mellitus.